Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
StatusCompleted No Results Posted
Indication/ConditionPostmenopausal Women With Advanced Breast Cancer
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
Inclusion Criteria: - Patients which participated in double blind study Exclusion Criteria: Patients with intolerable toxicity. Patients which confirmed progressive disease during double blind study. Patients which have received concurrent anti-cancer therapy during double blind study.